Please ensure Javascript is enabled for purposes of website accessibility

Why Immatics Stock Is Soaring Today

By Prosper Junior Bakiny - Updated Mar 17, 2021 at 9:44PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors liked the company's latest clinical update.

What happened

Shares of Immatics (IMTX 0.43%) were trading higher on Wednesday after the biopharmaceutical company announced positive data from a phase 1 clinical trial for several of its pipeline candidates. As of 3:25 p.m. EDT, Immatics' stock was up by 25.9%, after soaring by as much as 58.4% earlier in the day. 

So what

Immatics focuses on innovative cancer treatments. Its adoptive cell therapy seeks to modify a patient's own T cells (white blood cells that bind to and instruct virus-infected cells to self-destruct) to better target and destroy cancer cells.

In a phase 1 study, Immatics administered several of its ACTengine pipeline candidates to 16 cancer patients whose previous treatments had been ineffective. The goal of the trial was to assess the safety, tolerability, and initial signs of clinical and biological efficacy of these therapies.

Rolled up dollar bills stacked in a ladder pattern.

Image source: Getty Images.

Data from 10 patients showed that nine of them achieved disease control, while eight of the 10 experienced tumor shrinkage, among other positive results. These experimental treatments were also generally well tolerated, with all adverse events being deemed "manageable."

CEO Cedrik Britten said, "While the focus of this readout was to evaluate safety and initial biological activity, these unexpected observations on first anti-tumor activity indicate the therapeutic potential for our ACTengine platform in solid cancer patients with considerable tumor burden."

Now what

While these results are encouraging, Immatics and its pipeline programs face a long and arduous process filled with potential regulatory obstacles, possible failures from clinical trials, and other problems. It is far too soon to know whether Immatics' master plan will work, and for that reason, long-term investors should probably keep away from this healthcare stock for now.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Immatics N.V. Stock Quote
Immatics N.V.
$6.98 (0.43%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.